142 related articles for article (PubMed ID: 8005815)
1. Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer.
Kim JH; Khil MS; Kim SH; Ryu S; Gabel M
Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):555-7. PubMed ID: 8005815
[TBL] [Abstract][Full Text] [Related]
2. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy.
Khil MS; Kim JH; Bricker LJ; Cerny JC
Cancer J Sci Am; 1997; 3(5):289-96. PubMed ID: 9327153
[TBL] [Abstract][Full Text] [Related]
3. Estramustine: a novel radiation enhancer in human carcinoma cells.
Ryu S; Gabel M; Khil MS; Lee YJ; Kim SH; Kim JH
Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):99-104. PubMed ID: 7916009
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitizing effect of estramustine in malignant glioma in vitro and in vivo.
Bergenheim AT; Zackrisson B; Elfverson J; Roos G; Henriksson R
J Neurooncol; 1995; 23(3):191-200. PubMed ID: 7673981
[TBL] [Abstract][Full Text] [Related]
5. Estramustine phosphate enhances the effects of hyperthermia and induces the small heat shock protein HSP27 in the human prostate carcinoma cell line PC-3.
Roigas J; Wallen ES; Loening SA; Moseley PL
Urol Res; 2002 May; 30(2):130-5. PubMed ID: 12086019
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
7. Estramustine potentiates the effects of irradiation on the Dunning (R3327) rat prostatic adenocarcinoma.
Widmark A; Damber JE; Bergh A; Henriksson R
Prostate; 1994; 24(2):79-83. PubMed ID: 8309847
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
Kelly WK; Zhu AX; Scher H; Curley T; Fallon M; Slovin S; Schwartz L; Larson S; Tong W; Hartley-Asp B; Pellizzoni C; Rocchetti M
Clin Cancer Res; 2003 Jun; 9(6):2098-107. PubMed ID: 12796374
[TBL] [Abstract][Full Text] [Related]
9. Estramustine sensitizes human glioblastoma cells to irradiation.
Yoshida D; Piepmeier J; Weinstein M
Cancer Res; 1994 Mar; 54(6):1415-7. PubMed ID: 8137240
[TBL] [Abstract][Full Text] [Related]
10. Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer.
Kitamura T
Int J Urol; 2001 Feb; 8(2):33-6. PubMed ID: 11240822
[TBL] [Abstract][Full Text] [Related]
11. In vitro studies of Taxol as a radiation sensitizer in human tumor cells.
Liebmann J; Cook JA; Fisher J; Teague D; Mitchell JB
J Natl Cancer Inst; 1994 Mar; 86(6):441-6. PubMed ID: 7907149
[TBL] [Abstract][Full Text] [Related]
12. The effects of pentoxifylline on the survival of human glioma cells with continuous and intermittent stereotactic radiosurgery irradiation.
Eley KW; Benedict SH; Chung TD; Kavanagh BD; Broaddus WC; Schmidt-Ullrich RK; Lin PS
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):542-50. PubMed ID: 12243834
[TBL] [Abstract][Full Text] [Related]
13. Radiation sensitization by estramustine studies on cultured human prostatic cancer cells.
Eklöv S; Essand M; Carlsson J; Nilsson S
Prostate; 1992; 21(4):287-95. PubMed ID: 1461806
[TBL] [Abstract][Full Text] [Related]
14. Radiation sensitizing effect of estramustine is not dependent on apoptosis.
Ståhlberg K; Kairemo K; Erkkilä K; Pentikäinen V; Sorvari P; Taari K; Dunkel L; Rannikko S
Anticancer Res; 2005; 25(4):2873-8. PubMed ID: 16080540
[TBL] [Abstract][Full Text] [Related]
15. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.
Kitamura T; Suzuki M; Nishimatsu H; Kurosaki T; Enomoto Y; Fukuhara H; Kume H; Takeuchi T; Miao L; Jiangang H; Xiaoqiang L
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S34-40. PubMed ID: 20094950
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
17. [Potentiation of focal ultrasound treatment of prostate adenocarcinoma by concomitant chemotherapy with estramustine phosphate and paclitaxel].
Paparel P; Chapelon JY; Curiel L; Rabilloud M; Chesnais S; Gelet A
Prog Urol; 2004 Feb; 14(1):40-6. PubMed ID: 15098750
[TBL] [Abstract][Full Text] [Related]
18. Ethacrynic acid: a novel radiation enhancer in human carcinoma cells.
Khil MS; Kim SH; Pinto JT; Kim JH
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):375-80. PubMed ID: 8567338
[TBL] [Abstract][Full Text] [Related]
19. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
Zelefsky MJ; Kelly WK; Scher HI; Lee H; Smart T; Metz E; Schwartz L; Fuks Z; Leibel SA
J Clin Oncol; 2000 May; 18(9):1936-41. PubMed ID: 10784635
[TBL] [Abstract][Full Text] [Related]
20. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Pharmacol; 1998 May; 55(9):1427-33. PubMed ID: 10076535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
